We report a 12-year-old girl who presented with recurrent angioedema on the face, trunk, and extremities, and concomitant marked weight gain for 5 years. During the episode, her white blood cell count increased to 47.7×109/L with 89.9% eosinophils, followed by elevated serum level of IL-5, IgE, IgM, and LDH. Histopathology showed perivascular eosinophilic infiltration and diffuse eosinophilic infiltration throughout the dermis. Possible causes of hypereosinophilia and eosinophilic infiltration of vital organs were ruled out. We also tested the FIP1L1/PDGFRa and ETV6/PDGFRβ fusion gene to exclude the possibility of myeloid and lymphatic vessel neoplasms. The patient was treated with methylprednisolone and discharged with an oral prednisolone taper, which resulted in complete remission of the edema and normalization of peripheral blood eosinophil count, serum IL-5 level, IgE, IgM, and LDH.
INTRODUCTION
Episodic angioedema with eosinophilia (EAE), also known as Gleich syndrome, is a rare and benign disease without involvement of the internal organs. Because of the absence of systemic involvement, clinicians can differentiate this syndrome from hypereosinophilic syndrome (HES).
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CASE REPORT
A 12-year-old girl was admitted to Jinling hospital in July 2012 due to a recurrent angioedema on the face, trunk, and extremities, with concomitant marked weight gain. Initially, in 2006 she presented with a pruritic erythema over her extremities. Gradually, she developed pronounced nonpitting edema on the face and extremities, often accompanied by arthralgia, beginning in 2010.
All symptoms disappeared spontaneously within a few days. The attacks became more severe and frequent, occurring monthly for nearly half a year. She had frequently been diagnosed with urticaria or angioedema and was prescribed oral or systemic glucocorticosteroids. The patient had no personal or family history of atopy and denied drug intake before the onset of her symptoms.
Physical examination revealed bilateral eyelid edematous erythema, angioedema of the face, trunk and extremities, and some pigment on the chin and cheek. The skin of the bilateral lower extremities was dry and rough, with some multiple pigmented macules ( Figure 1 ). Other skin sites were normal.
Laboratory investigation showed an elevated white cell count of 47. 
DISCUSSION
EAE was first described by Gleich in 1984. 2 The majority of cases were reported in the United States, Europe, and Japan. NEAE, which is a second type of EAE, has some different characteristics from EAE, including the absence of recurrent attacks, predominance of young females, angioedema localized on the extremities, normal IgM levels, and no necessity for corticosteroid therapy. In 8 out of 11 cases of NEAE described by Nakachi, 5 patients did not receive corticosteroid treatment. He found these patients' eosinophil count returned to normal levels within 8 weeks with no recurrence.
The pathogenesis of EAE is not completely understood. In our patient, IL-5 serum level rose concomitantly with the peak of eosinophilia in the acute phase of the attack. After corticosteroids were started, IL-5 serum level dropped to normal limit, concomitant with the clinical remission and eosinophils. IL-5 is a specific hematopoietic growth factor that is responsible for the growth and differentiation of eosinophils. Several studies have demonstrated that it may participate in the inflammatory reaction of EAE. 1, 6 Some studies showed that C5aR, IL-1, IL-6, and soluble interleukin-2 receptor (sIL-2R) also play a role in the pathophysiology of EAE. 1, 7 Corticosteroids remain the first-line therapeutic option for patients with EAE due to their dual suppressive action on eosinophils proliferation and T-cell cytokine production. There is usually a dramatic fall in eosinophil counts and an improvement in EAE symptoms following corticosteroid therapy. Scranton reported 1 case of EAE successfully treated with imatinib mesylate, which was successful for FIP1L1/PDGFRa-positive hypereosinophilic patients. 8 Scranton thought that the good response to imatinib might be due to an imatinib-sensitive mutant kinase similar to that seen in hypereosinophilic syndromes (HES) or chronic myeloid leukemia.
He proposed that imatinib could be considered for patients with EAE who require prolonged or recurrent treatment with systemic corticosteroids, even without a demonstrable fusion gene. Our patient was treated with prednisolone and tapered to 10 mg/daily without recurrence and did not develop any internal organ involvement.
Although the rarity of EAE makes it difficult to diagnose, physicians should consider the disease in the case of patients with eosinophilia associated with angioedema. q 
